Skip to content
Clinical Trials – home
The NetherlandsBack to the Netherlands

Clinical trials in Dordrecht – page 14

1 624 clinical trials in Dordrecht, The Netherlands across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

The NetherlandsOur site in the NetherlandsKlinischOnderzoek.nl(opens in a new tab)
Dordrecht at a glance
1 624
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 624 trials in Dordrecht

Open in trial search

Phase 2 Study of Rinatabart Sesutecan with Pegfilgrastim in Adults with Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Glatiramer Acetate
  • Sponsor:Genmab A/S

Study of belantamab mafodotin with drug combination in adults aged 18 years and older with relapsed or refractory multiple myeloma

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Belantamab Mafodotin
  • Sponsor:Glaxosmithkline Research & Development Limited

Crohn's disease

Recruiting

An observational study on the use of methotrexate in children and adolescents with Crohn's disease

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years
  • Substances:Methotrexate
  • Sponsor:Amsterdam UMC Stichting

A study to evaluate the safety and effectiveness of AAVB-039 in patients with Stargardt disease

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years
  • Substances:COMBINATION OF TWO ADENO-ASSOCIATED VIRAL VECTORS OF SEROTYPE 8 CONTAINING THE 5'- AND THE 3'- HALF CODING SEQUENCES OF HUMAN ABCA4 FUSED TO INTEINS
  • Sponsor:Aavantgarde Bio S.r.l.

A study to evaluate the efficacy and safety of depemokimab and salbutamol sulfate in patients with chronic obstructive pulmonary disease and type 2 inflammation.

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Depemokimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Study of pembrolizumab, capecitabine, or olaparib in patients with early-stage triple negative breast cancer and remaining disease after initial treatment

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

A study to evaluate the safety of VTx-002 in patients with amyotrophic lateral sclerosis.

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:VTX-002
  • Sponsor:VectorY Therapeutics B.V.

Comparing sotorasib and pembrolizumab with chemotherapy for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Amgen Inc.

A study of rilvegostomig and ramucirumab in patients with advanced or metastatic non-small cell lung cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Ramucirumab
  • Sponsor:Astrazeneca AB

A study of rilvegostomig, cisplatin, and gemcitabine compared to durvalumab and a drug combination for adults with advanced biliary tract cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Astrazeneca AB

A study to evaluate the effects of CSX-1004 on breathing difficulties caused by fentanyl in healthy adults and people with opioid use disorder

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · Healthy volunteers
  • Substances:CSX-1004
  • Sponsor:Cessation Therapeutics Inc.

Bronchiectasis

Recruiting

A study to evaluate the safety and effectiveness of AZD0292 in people aged 12 years and older with bronchiectasis and chronic Pseudomonas aeruginosa infection

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:AZD0292
  • Sponsor:Astrazeneca AB

Other cities in the Netherlands

The busiest research cities in the country

All 101 cities in the Netherlands

Clinical research in Dordrecht

What the registry says about research in the country

01 Hematologic Oncology

Innovative research focusing on Acute Myeloid Leukemia (AML) and various forms of Multiple Myeloma, evaluating novel drug combinations and treatment approaches for patients ineligible for intensive chemotherapy.

  • Blood Cancer Therapies
  • Leukemia Treatment
  • Novel Drug Combinations

Studies aim to improve survival rates and treatment outcomes in previously untreated patients.

02 Cardiovascular Medicine

Research centered on atherosclerotic cardiovascular disease and deep vein thrombosis, investigating new therapeutic approaches and preventive strategies.

  • Heart Disease Management
  • Blood Clot Prevention
  • Cardiac Interventions

Clinical trials focus on improving patient outcomes through innovative treatments and prevention strategies.

03 Endocrine Disorders

Studies examining treatments for thyroid conditions and hormonal disorders, comparing conventional and innovative therapeutic approaches.

  • Thyroid Disease Management
  • Hormone Therapy
  • Quality of Life Improvement

Research aims to enhance treatment efficacy while minimizing side effects.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease? Our clinical trial advisor will do it for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.